Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...

Under the settlement, Mainers who are uninsured or have commercial health insurance will be eligible to purchase monthly ...

The drugs are listed in alphabetical order. Aprepitant oral suspension: Merck reported a shortage of Emend, its aprepitant oral suspension. Merck did not provide a reason for the shortage. The ...

In ulcerative colitis, duvakitug led to clinical remission in up to 48% of patients, with placebo-adjusted rates of 27% at the highest dose. In Crohn's disease, duvakitug achieved endoscopic ...

Sanofi’s MERILOG™ is now the first insulin aspart biosimilar, and the third insulin biosimilar product to be approved by the FDA, behind Biocon’s SEMGLEE® (insulin glargine-yfgn ...

Sanofi will provide Merilog to patients for $35 or less for ... In 2021, the FDA approved two biosimilars of Lantus, an insulin glargine: Rezvoglar (insulin glargine-aglr) in December 2021 and Semglee ...

More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency ...

In 2023, Sanofi jumped the bandwagon with the other two insulin U.S. giants to lower the price of its best-selling insulin product, Lantus (insulin glargine), by 78%. Sanofi said it would cap a ...

In March 2023, Sanofi and Novo came under fire from Sen. Bernie Sanders (I-Vt), who asked the companies to follow in the footsteps of fellow diabetes leader Eli Lilly and lower the price of their ...

The FDA granted approval of Merilog to Sanofi (SNY)-Aventis U.S. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top ...

Please provide your email address to receive an email when new articles are posted on . The drug, which is the first rapid-acting biosimilar, is meant to treat blood sugar spikes at mealtimes.